Who are Ametris's investors?

Ametris's investors include ARCHIMED Japan.

Ametris

1 known investors

Find your way into Ametris

59 people in our graph share verified history with the Ametris team — schools, employers, funds. One of them is your warm intro.

Kevin Cooperunlockedknows Jeremy Wyatt · together at UWF Lewis Bear Jr. College of Business (overlapped)

×11knows the team · via University of Florida

Ametris provides sensor-based digital measures and digital endpoints for clinical trials, capturing data from wearable sensors and real-world patient insights. Now part of Signant Health, it supports clinical trial sponsors running decentralized, hybrid, and traditional studies alongside electronic Clinical Outcome Assessment (eCOA) capabilities.

AI & Machine Learning Biotech Deep Tech Digital Health Healthtech Medical Devices

Founders & leadership

Jeremy Wyatt Chief Executive OfficerJeremy Wyatt co-founded Ametris (now part of Signant Health), which provides wearable sensor-based data collection and digital endpoints for clinical trials. He previously worked at ActiGraph, where he developed medical-grade activity monitoring solutions and analytics for research and pharmaceutical applications.

Investors · 1

ARCHIMED Japanlisted by ARCHIMED JapanLyon · $10.8M – $1.1B

How we know: ARCHIMED Japan's portfolio page · Not right? Tell us

Frequently asked questions

What does Ametris do?: Ametris provides sensor-based digital measures and digital endpoints for clinical trials, capturing data from wearable sensors and real-world patient insights. Now part of Signant Health, it supports clinical trial sponsors running decentralized, hybrid, and traditional studies alongside electronic Clinical Outcome Assessment (eCOA) capabilities.
Who are Ametris's investors?: Ametris's investors include ARCHIMED Japan.